Zymeworks upgraded by H.C. Wainwright with a new price target
$ZYME
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright upgraded Zymeworks from Neutral to Buy and set a new price target of $26.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2025 | $26.00 | Neutral → Buy | H.C. Wainwright |
| 10/10/2025 | $30.00 | Buy | B. Riley Securities |
| 5/20/2025 | Buy | TD Cowen | |
| 12/16/2024 | $18.00 | Neutral → Overweight | Analyst |
| 11/7/2024 | $10.00 → $25.00 | Market Perform → Outperform | Leerink Partners |
| 11/1/2024 | $12.00 | Overweight → Equal Weight | Wells Fargo |
| 3/21/2023 | $12.00 | Overweight | Wells Fargo |
| 1/4/2023 | $10.00 → $8.00 | Neutral | H.C. Wainwright |
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its third quarter 2025 financial results after market close on November 6, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 6, 2025 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and w
USA News Group News Commentary –Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development is accelerating across oncology as companies advance novel mechanisms targeting previously difficult-to-treat patient populations. The cancer immunotherapy market reached $226 billion in 2024 and continues expanding rapidly, driven by precision approaches that pair targeted agents with immunotherapy, identify genetic vulnerabilities, and deploy radioligand therapies for metastatic disease[1]. Recent clinical data demonstrating high response rates in biomarker-selected populations underscore the shift toward mole
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer.Data from the Phase 1 trial of ZW191 provide readthrough to Zymeworks' broader ADC portfolio utilizing its novel bystander active topoisomerase-1 inhibitor payload, ZD06519. VANCOUVER, British Columbia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammat
4 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
3 - Zymeworks Inc. (0001937653) (Issuer)
H.C. Wainwright upgraded Zymeworks from Neutral to Buy and set a new price target of $26.00
B. Riley Securities initiated coverage of Zymeworks with a rating of Buy and set a new price target of $30.00
TD Cowen initiated coverage of Zymeworks with a rating of Buy
8-K - Zymeworks Inc. (0001937653) (Filer)
SCHEDULE 13G/A - Zymeworks Inc. (0001937653) (Subject)
8-K - Zymeworks Inc. (0001937653) (Filer)
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer. In this role, Dr. Schayowitz will report directly to Zymeworks' Chair & Chief Executive Officer, Kenneth Galbraith, and work closely with the Zymeworks R&D and Business Development teams to advance the Company's broad portfolio of nominated product candidates, while also
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointments of Greg Ciongoli and Robert E. Landry to the Company's Board of Directors, effective August 10, 2025. Mr. Ciongoli and Mr. Landry were also appointed as members of the audit committee of the Board of Directors. "Greg and Bob bring extensive financial and strategic leadership expertise that will be invaluable to Zymeworks, as we continu
VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023,
SC 13G/A - Zymeworks Inc. (0001937653) (Subject)
SC 13G/A - Zymeworks Inc. (0001937653) (Subject)
SC 13G - Zymeworks Inc. (0001937653) (Subject)
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its third quarter 2025 financial results after market close on November 6, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 6, 2025 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and w
Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW251 with first-in-human studies planned to initiate in 2025China and European approval for zanidatamab in 2L HER2-positive biliary tract cancer (BTC) expands international patient access$48.7 million in revenue for 2Q-2025 from continued progress on existing partnerships Ziihera® net product sales by Jazz were $5.5 million for 2Q-2025Cash resources of $333.4 million as of June 30, 2025 (compared to $324.2 million as of December 31, 2024), which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into 2H-2027Will host conference ca
VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its second quarter 2025 financial results after market close on August 7, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on August 7, 2025 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webca